DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for inborn carbohydrate metabolic disorder — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleInborn carbohydrate metabolic disorder maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for inborn carbohydrate metabolic disorder is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
glucokinase (GCK) — GCK is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4DCH · 1.79 Å · ligand (2R)-3-cyclopentyl-2-[4-(methylsulfonyl)phenyl]-N-(1,3-thiazol-2-yl)propanamide (4DC). Experimental structure, not a prediction.
What the evidence adds up to
Inborn errors of metabolism are a group of conditions defined by an altered metabolic pathway, and their cumulative prevalence is at least greater than 1 in 2000 newborns. A 2021 review notes that while numerous guidelines exist for diagnosing and managing these disorders in children, there are none for adults. The same review states that early recognition and appropriate therapy would improve clinical outcome, but it provides no concrete survival or response rate data to support that claim.
A 2010 review focuses on protein-dependent inborn errors, which are caused by inherited enzyme defects in amino acid catabolism or transport. These disorders usually have low prevalence except in communities with high consanguinity rates, and they result in intoxication from accumulated metabolites such as ammonia. No specific drug treatment or efficacy data are reported in that abstract.
A 2023 review discusses the expansion of newborn screening to include disorders of carbohydrate, lipid, and protein metabolism. It emphasises that effective treatment requires comprehensive nutrition and medical management, and it highlights the role of metabolic dietitians. No drug, no survival figure, and no response rate are given.
What is missing is any controlled trial data comparing a specific drug to standard care in adult patients with inborn carbohydrate metabolic disorders. The existing literature is limited to reviews and guidelines, with no randomised evidence, no patient stratification by genotype or phenotype, and no dedicated funding for adult-focused therapeutic trials.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Diagnostics · 2021 · 13 citations · open access
Diagnosis and Management of Inborn Errors of Metabolism in Adult Patients in the Emergency Department
AbstractInborn errors of metabolism (IEM) constitute an important group of conditions characterized by an altered metabolic pathway. There are numerous guidelines for the diagnosis and management of IEMs in the pediatric population but not for adults. Given the increasing frequency of this group of conditions in adulthood, other clinicians in addition to pediatricians should be aware of them and learn to identify their characteristic manifestations. Early recognition and implementation of an appropriate therapeutic approach would improve the clinical outcome of many of these patients. This review presents when and how to investigate a metabolic disorder with the aim of encouraging physicians not to overlook a treatable disorder.
Archives of Pediatrics and Adolescent Medicine · 1981 · 4 citations
Inherited Disorders of Carbohydrate Metabolism
AbstractThis monograph contains the proceedings of the 16th Annual Symposium on Inherited Disorders of Carbohydrate Metabolism of the Society for the Study of Inborn Errors of Metabolism, held in Bristol, England, July 12 to 14, 1978. About 25 invited speakers and 150 participants from Europe and North America contributed to this well-balanced conference, which so effectively combined clinical and scientific interests. The result is an excellent state-of-the-art presentation covering six interesting and important, albeit rare, disorders of carbohydrate metabolism. To be sure, this book fulfills the goals of the Society, which "exists to promote exchanges of ideas between workers in different disciplines who are interested in any aspect of inborn metabolic disorders." Thus, in the first section, H. G. Hers presents a brilliant summary of the basic biochemistry of carbohydrate regulation as of 1978. This is followed in section 2 by two chapters on carbohydrate malabsorption, which tend to be
Oxford University Press eBooks · 2010 · 1 citations
Protein-dependent inborn errors of metabolism
AbstractProtein-dependent inborn errors of metabolism are caused by inherited enzyme defects of catabolic pathways or intracellular transport of amino acids. Most result in an accumulation of metabolites upstream of the defective enzyme (amino acids and/or ammonia), causing intoxication. Protein-dependent metabolic diseases usually have a low prevalence except for some high-risk communities with high consanguinity rates. However, the cumulative prevalence of these disorders is considerable (i.e. at least >1:2000 newborns) and represents an important challenge for all public health systems....
Role of Metabolic Nutrition in Newborn Screening and Inherited Metabolic Disorders
AbstractThe expansion of newborn screening (NBS) encompasses a wide range of inherited metabolic disorders, including disorders of carbohydrate, lipid, and protein metabolism. Effective treatment of these disorders requires comprehensive nutrition and medical management. This review highlights the intricacies of medical nutrition therapy for several common metabolic disorders and underscores the crucial role of metabolic dietitians in managing these patients.
Revista chilena de pediatría · 2014 · 0 citations · open access
Actualización en el manejo agudo de errores congénitos del metabolismo
AbstractInborn metabolic disorders are genetic diseases which are uncommon each one, but together they are not. They are characterized by an enzimatic defect that blocks a metabolic pathway, producing specific signs and symptoms. The current article pretends be an updated guideline for their acute management which is based on: 1) Inmediate life support, hydroelectrolyte balance and sample procurement, 2) Avoiding the production of toxic endogenous metabolites and anabolism promotion, 3) The supplementation of substrates and 4) The removal of toxic substances. Their prompt suspicious, identification and treatment starting will be crucial for neurological prognosis and prevention of death.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
